TENAYA, LUCERNE year 2 data reveals promising results for faricimab
Scott Walter, MD, an investigator in the TENAYA and LUCERNE trials discusses the year 2 data for the treat-and-extend regimen of faricimab for the treatment of nAMD and DME.
How to diagnose geographic atrophy earlier
Carl Danzig, MD, points out that the sooner patients can be diagnosed, the sooner ophthalmologists can treat them and preserve their vision.
Samsara Vision update: Concerto trial recruiting patients with late-stage AMD
Tom Ruggia, President and CEO of Samsara Vision, provides updates on the lead asset for late-state age-related macular degeneration: Smaller-incision, new generation, implantable miniature telescope (SING IMT).
AAO 2022 recap: Research updates, innovations on the horizon presented at the Annual Meeting
A combination of posters, podium presentations, and instructional courses provided invaluable revelations to the ophthalmic community.
Risk of rhegmatogenous retinal detachment rises following cataract surgery
The investigators undertook a study to determine the incidence of rhegmatogenous retinal detachments 1 year after cataract using the IRIS Registry data and to determine the demographic features, ocular comorbidities, and intraoperative factors associated with an increased risk of detachment development.
Identifying risk factors for development of rhegmatogenous retinal detachments in fellow eyes
Patients with a unilateral rhegmatogenous retinal detachment frequently ask about the risk of developing an RRD in their fellow eye.
Fewer ocular symptoms linked to e-cigarettes than traditional cigarettes
Those who used both traditional and electronic cigarettes reported severe to very severe ophthalmic symptoms.
Faricimab for nAMD: Safe, effective, lower treatment burden compared with aflibercept in pooled TENAYA, LUCERNE Phase 3 trials
The AVONELLE-X long-term extension study will continue to evaluate the efficacy, durability, and safety of faricimab in patients with neovascular AMD.
Health care restrictions due to COVID-19 had no negative effects on status of DME
The data analysis showed that the macular thickness decreased across all time periods and in all macular regions for all tertiles.
Late-breaking: Janssen announces data from 2 gene therapy programs
Janssen noted that results from Phase 1/2 MGT009 study demonstrate safety profile of investigational gene therapy botaretigene sparoparvovec (AAV-RPGR) and suggest sustained vision improvement in patients with X-linked retinitis pigmentosa.
Acute retinal necrosis: Retinal detachment rates are unaffected by early treatment with intravitreal antivirals, vitrectomy
The results also showed that, compared to use of systemic antivirals alone, treatment with adjunctive intravitreal injections or early pars plana vitrectomy did not affect the time to development of retinal detachments.
Faricimab eradicates center-involved DME faster than aflibercept
The data analysis indicated that patients achieved robust visual gains and central subfield thickness reductions with faricimab dosed every 8 weeks and with PTI dosing up to every 16 weeks. The gains were sustained through year 2 of the trials.
Understanding fluid dynamics in wet macular degeneration
At AAO 2022, Justis Ehlers, MD, presented a talk entitled, "Defining the Fluid Problem in Neovascular AMD: To Dry or Not to Dry?"
IRIS Registry: Comparing dry eye disease in adult and pediatric populations
Almost 5 million patients in the IRIS Registry had received at least one diagnosis of DED between 2013 and 2019; of those, 203,171 were children under 18 years of age and 4,592,808 were adults.
Continuous range-of-motion IOL scores high in patient satisfaction
Investigators reported that the safety and efficacy of the Tecnis Synergy IOL model ZFR00V indicates that it may be a good option for patients who desire meaningful gains in uncorrected visual acuity at all distances.
Pediatric patients have higher incidence of new strabismus following tube shunt surgery than adult patients
13% of pediatric patients had new-onset strabismus after a tube shunt procedure; in contrast, 0% of adults had new-onset strabismus after tube shunt surgery (at 6 months or at last follow-up).
YOSEMITE, RHINE treat-and-extend data show favorable results for faricimab for the treatment of DME
Roger A. Goldberg, MD, MBA, discusses his 2022 AAO poster: "T&E-Based Personalized Treatment Interval Dynamics in the YOSEMITE/RHINE Trials of Faricimab in DME."
Poll results: Do you plan to attend the 2022 AAO Meeting?
Results from our recent poll regarding AAO 2022 attendance indicate that most ophthalmologists and retina specialists plan to participate in the Annual Meeting in person in Chicago, Illinois.
POLL: Are you planning to attend the AAO 2022 Meeting?
A poll for retina specialists regarding their attendance at the 2022 American Academy of Ophthalmology Meeting in Chicago, Illinois. The poll is now closed.
AAO to land in Chicago: Subspecialty days, symposia to showcase scientific achievement
The American Academy of Ophthalmology annual meeting is coming to Chicago, Illinois, from September 30 to October 3, featuring Subspecialty Days and a virtual component.
5 tips for contract negotiations for young ophthalmologists
Lisa Nijm, MD, advises young ophthalmologists on how to find common ground with their preferred practice and find solutions in the negotiation process that will help both parties flourish.
Monte Carlo simulation indicates positive outcomes for anti-VEGF therapy in severe NPDR
Dr. Quan Dong Nguyen reviews a Monte Carlo simulation that showed evidence that treating severe NPDR with anti-VEGF therapy garners positive results.
New programs available for residents at the Jules Stein Eye Institute
Dr. Stacy Pineles discusses the additional degree opportunities within the residency program at the Jules Stein Eye Institute at UCLA.
VIVID/VISTA data study: Baseline factors affect DME resolution
Dr. Katherine Talcott discusses baseline factors—CST thickness, hemoglobin A1C, and baseline vision—and their effects on DME resolution.
Ophthalmic bevacizumab effectively treats wet macular degeneration, NORSE TWO concludes
Firas Rahhal, MD, discusses Outlook Therapeutics’ Phase 3 pivotal NORSE TWO trial for ONS-5010.
Using the IRIS registry to analyze ancillary testing patterns on a per patient basis
Ted Leng, MD, discusses his presentation, “Variations in Vitreoretinal Physician Utilization of Ancillary Testing: An IRIS Registry Analysis” during Retina Specialty Day at AAO 2021.
AAO 2021 reinvigorates ophthalmologists for 2022
Dr. McDonnell highlights inspiring moments from the 2021 annual meeting of the American Academy of Ophthalmology, along with a look ahead to next year’s conference in Chicago.
Reflecting on key takeaways from AAO 2021 with Peter J. McDonnell, MD
Peter J. McDonnell, MD, shares some of many highlights from this year’s annual meeting of the American Academy of Ophthalmology in New Orleans.
Brolucizumab shows evidence of retinal drying in wet AMD
Jill Hopkins, MD, discusses results from phase 3a of the Merlin trial for brolucizumab as a treatment for wet AMD and provides updates on KESTREL and KITE trials for the treatment of diabetic macular edema.
ARMOR study: data sheds light on antibiotic resistance in ophthalmology
At the 2021 American Academy of Ophthalmology annual meeting, Penny Asbell, MD, FACS, MBA, discussed data from the ARMOR study and its effects on treating ophthalmic infections, such as endophthalmitis.
2 Clarke Drive Cranbury, NJ 08512